Sinopharm Tech Holdings Limited (HK:8156)

:8156

8156

Sinopharm Tech Holdings Limited

RESEARCH TOOLSreports

Want to see HK:8156 full AI Analyst Report?

Sinopharm Tech Holdings Limited (8156) Price & Analysis

0 Followers

8156 Stock Chart & Stats

HK$0.22

HK$0.00(0.00%)

At close: Sep 30 4:00 PM EDT

HK$0.22

HK$0.00(0.00%)

Day’s Range― - ―

52-Week RangeHK$0.14 - HK$0.44

Previous CloseN/A

Volume194.40K

Average Volume (3M)157.92K

Market Cap

HK$133.08M

Enterprise ValueHK$175.93M

Total Cash (Recent Filing)HK$6.95M

Total Debt (Recent Filing)HK$46.73M

Price to Earnings (P/E)40.5

Beta0.46

Next Earnings

Sep 25, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding633,693,050

10 Day Avg. Volume46,340

30 Day Avg. Volume157,918

Financial Highlights & Ratios

PEG Ratio0.99

Price to Book (P/B)-2.33

Price to Sales (P/S)1.40

P/FCF Ratio-11.93

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Revenue GrowthSustained triple‑digit revenue growth indicates meaningful demand expansion and product‑market fit in its software application market. Over 2–6 months this supports scaling opportunities, gives management room to improve unit economics, and underpins long‑term revenue runway if margins recover.

Improving Free Cash FlowAn improving free cash flow trend signals the company is moving toward cash generation capacity despite current challenges. This durable improvement can reduce future financing needs, enable reinvestment in product development or customer acquisition, and support operational sustainability if maintained.

Lean, Scalable Software Cost BaseA small employee base in a Software - Application business implies a lean cost structure and inherent scalability—software can scale revenue without commensurate headcount increases. Over months this structural advantage can translate to faster margin recovery once revenue growth stabilizes and fixed costs are absorbed.

Bears Say

Negative Shareholders' EquityNegative equity is a deep solvency weakness that persists beyond short‑term cycles. It constrains financing options, raises lender and supplier risk perceptions, and limits strategic flexibility. Over 2–6 months this materially increases the risk of covenant breaches or distress if profitability and cash flow do not improve.

Negative Operating Cash FlowPersistent negative operating cash flow undermines the company’s ability to self‑fund growth and operations. Even with improving free cash flow, ongoing operational cash deficits force reliance on external funding or asset sales, heightening liquidity risk and limiting capacity to invest in long‑term product or market expansion.

Ongoing Unprofitability And Weak MarginsSustained negative margins reflect structural issues in converting revenue to profit. Continued losses erode retained capital, hinder reinvestment, and make margin improvement necessary before the business can sustainably scale. This remains a material headwind for durable financial recovery.

8156 FAQ

What was Sinopharm Tech Holdings Limited’s price range in the past 12 months?

Sinopharm Tech Holdings Limited lowest stock price was HK$0.14 and its highest was HK$0.44 in the past 12 months.

What is Sinopharm Tech Holdings Limited’s market cap?

Sinopharm Tech Holdings Limited’s market cap is HK$133.08M.

When is Sinopharm Tech Holdings Limited’s upcoming earnings report date?

Sinopharm Tech Holdings Limited’s upcoming earnings report date is Sep 25, 2026 which is in 96 days.

How were Sinopharm Tech Holdings Limited’s earnings last quarter?

Sinopharm Tech Holdings Limited released its earnings results on Feb 26, 2026. The company reported -HK$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.006.

Is Sinopharm Tech Holdings Limited overvalued?

According to Wall Street analysts Sinopharm Tech Holdings Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sinopharm Tech Holdings Limited pay dividends?

Sinopharm Tech Holdings Limited does not currently pay dividends.

What is Sinopharm Tech Holdings Limited’s EPS estimate?

Sinopharm Tech Holdings Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sinopharm Tech Holdings Limited have?

Sinopharm Tech Holdings Limited has 633,693,050 shares outstanding.

What happened to Sinopharm Tech Holdings Limited’s price movement after its last earnings report?

Sinopharm Tech Holdings Limited reported an EPS of -HK$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.273%.

Which hedge fund is a major shareholder of Sinopharm Tech Holdings Limited?

Currently, no hedge funds are holding shares in HK:8156

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sinopharm Tech Holdings Limited

Sinopharm Tech Holdings Limited functions as an investment holding enterprise, with its primary focus on lottery operations across mainland China and Hong Kong. The company diversifies its activities into several key areas: it supplies both hardware and software systems for lottery services; develops and implements "Internet Plus" solutions for various industries including healthcare, government administration, property leasing, and public security; engages in the manufacturing and distribution of personal protective equipment; and offers additional services such as corporate management, supply chain optimization, data analytics, and online trading of goods. Founded in 1999 and headquartered in Sha Tin, Hong Kong, the company rebranded to Sinopharm Tech Holdings Limited in June 2019, having previously traded as China Vanguard You Champion Holdings Limited.